2 Stocks That Have Doubled This Year and Are Still Worth Buying

Shares of TransMedics Group (TMDX) and FuboTV (FUBO) have more than doubled this year, driven by distinct company-specific catalysts. TransMedics' surge is attributed to strong Q1 financial performance, including 48% revenue growth and doubled EPS, and raised FY2025 guidance, validating its innovative Organ Care System technology for organ preservation. FuboTV's significant appreciation stems from its strategic merger with Disney's Hulu+ Live TV, which diversifies its content, mitigates competitive threats, provides substantial capital infusion, and secures Disney's majority ownership, positioning it for sustained growth in the evolving streaming landscape.

Analysis

TransMedics Group (TMDX) and FuboTV (FUBO) have materially outperformed the broader market, with shares more than doubling year-to-date on the back of distinct, fundamental catalysts. TransMedics overcame negative sentiment from a short-seller report by delivering strong first-quarter results, including a 48% year-over-year revenue increase to $143.5 million and a doubling of earnings per share to $0.70. This performance, coupled with raised full-year 2025 guidance, validates the market potential of its Organ Care System (OCS) technology, which improves transplant organ viability and utilization rates. Meanwhile, FuboTV's recent appreciation is driven by its strategic merger with Disney's Hulu+ Live TV. This transaction is transformative, as it not only diversifies FuboTV's offering beyond its sports niche but also neutralizes a significant competitive threat by cancelling the planned Venu streaming service. The deal significantly improves FuboTV's capital position through a $220 million infusion and a $145 million term loan, and strategically aligns it with Disney, which is now its majority shareholder, positioning it more favorably within the expanding streaming market.

Key Decisions for Investors

• Investors should assess TransMedics based on its fundamental growth trajectory, as its strong Q1 performance and innovative OCS technology suggest a durable long-term thesis despite the stock's significant recent appreciation.
• The FuboTV investment case has been fundamentally altered by the Hulu+ Live TV merger; consider that the company is now a more diversified and strategically-backed entity with reduced competitive and financial risk.
• Given that both stocks have more than doubled in six months, prospective investors should be mindful of potential volatility and may consider phasing into positions rather than making a full allocation at current levels.
• Monitor TransMedics' ability to continue capturing market share and improving organ utilization rates, as these are key drivers for sustaining its growth beyond the initial financial turnaround.
• For FuboTV, track the integration progress with Hulu+ Live TV and any commentary from its new majority shareholder, Disney, as these will be critical indicators of its long-term success in the competitive streaming landscape.